1. Enzyme replacement therapies: what is the best option?

Azam Safary , Mostafa Akbarzadeh Khiavi , Rahimeh Mousavi, Jaleh Barar , Mohammad A Rafi*

Bioimpacts. 2018;8(3): 153-157. doi: 10.15171/bi.2018.17

PMCID: PMC6128977 PMID: 30211074 Scopus ID: 85050655722

Article

PDF

Full Text

XML

Cited By:

Editorial

2. Achievements and beyond: Scientific trajectory of Professor Mohammad A. Rafi

Yadollah Omidi , Abass Alavi*

BioImpacts. 2021;11(1): 1-4. doi: 10.34172/bi.2021.01

PMCID: PMC7803920 PMID: 33469502 Scopus ID: 85099192222

Article

PDF

Full Text

XML

Cited By:

Mohammad Rafi (Persian: محمد رفیع ) obtained his PhD from University of Montpellier, France, in 1970. Investigating lysosomal storage diseases, he focused on gene therapy of neurodegenerative disorders using globoid cell leukodystrophy (Krabbe disease) animal models. With successful AAVrh10-mediated therapy in animal models, his research is moving towards human clinical trials.

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons